Next Article in Journal
Advances in Pharmacological Properties, Molecular Mechanisms, and Bioavailability Strategies of Chlorogenic Acid in Cardiovascular Diseases Therapy
Previous Article in Journal
Nasal Administration of Durvillaea antarctica Fucoidan Inhibits Lung Cancer Growth in Mice Through Immune Activation
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 18
Issue 9
10.3390/ph18091355
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Correction to Pharmaceuticals 2023, 16(5), 749.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Hou et al. S-72, a Novel Orally Available Tubulin Inhibitor, Overcomes Paclitaxel Resistance via Inactivation of the STING Pathway in Breast Cancer. Pharmaceuticals 2023, 16, 749

by
Zhenyan Hou
1,
Songwen Lin
1,2,
Tingting Du
1,
Mingjin Wang
1,
Weida Wang
1,
Shen You
1,
Nina Xue
1,
Yichen Liu
1,
Ming Ji
1,2,*,
Heng Xu
1,* and
Xiaoguang Chen
1,3,*
1
State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
2
Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
3
Beijing Key Laboratory of Non-Clinical Drug Metabolism and PK/PD Study, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
*
Authors to whom correspondence should be addressed.
Pharmaceuticals 2025, 18(9), 1355; https://doi.org/10.3390/ph18091355
Submission received: 10 July 2025 / Accepted: 2 September 2025 / Published: 10 September 2025
Versions Notes

Error in Funding

In the original publication [1], there are errors in the Funding Number. The authors state that the scientific conclusions are unaffected. The corrected version appears below. This correction was approved by the Academic Editor. The original publication has also been updated.
  • Funding: This work was supported by the National Natural Science Foundation of China (grant nos. 82104202 and 81903904) and the CAMS Innovation Fund for Medical Science (CIFMS) (CAMS Innovation Fund for Medical Science (CIFMS) (2021-I2M-1-026)).

Error in Figure

In the original publication [1], there was a mistake in Figure 4F as published. The HE data in the paclitaxel group was missing and unintentionally pasted as that of the vehicle group due to carelessness. The corrected Figure 4F appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Pharmaceuticals 18 01355 i001

Reference

  1. Hou, Z.; Lin, S.; Du, T.; Wang, M.; Wang, W.; You, S.; Xue, N.; Liu, Y.; Ji, M.; Xu, H.; et al. S-72, a Novel Orally Available Tubulin Inhibitor, Overcomes Paclitaxel Resistance via Inactivation of the STING Pathway in Breast Cancer. Pharmaceuticals 2023, 16, 749. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Hou, Z.; Lin, S.; Du, T.; Wang, M.; Wang, W.; You, S.; Xue, N.; Liu, Y.; Ji, M.; Xu, H.; et al. Correction: Hou et al. S-72, a Novel Orally Available Tubulin Inhibitor, Overcomes Paclitaxel Resistance via Inactivation of the STING Pathway in Breast Cancer. Pharmaceuticals 2023, 16, 749. Pharmaceuticals 2025, 18, 1355. https://doi.org/10.3390/ph18091355

AMA Style

Hou Z, Lin S, Du T, Wang M, Wang W, You S, Xue N, Liu Y, Ji M, Xu H, et al. Correction: Hou et al. S-72, a Novel Orally Available Tubulin Inhibitor, Overcomes Paclitaxel Resistance via Inactivation of the STING Pathway in Breast Cancer. Pharmaceuticals 2023, 16, 749. Pharmaceuticals. 2025; 18(9):1355. https://doi.org/10.3390/ph18091355

Chicago/Turabian Style

Hou, Zhenyan, Songwen Lin, Tingting Du, Mingjin Wang, Weida Wang, Shen You, Nina Xue, Yichen Liu, Ming Ji, Heng Xu, and et al. 2025. "Correction: Hou et al. S-72, a Novel Orally Available Tubulin Inhibitor, Overcomes Paclitaxel Resistance via Inactivation of the STING Pathway in Breast Cancer. Pharmaceuticals 2023, 16, 749" Pharmaceuticals 18, no. 9: 1355. https://doi.org/10.3390/ph18091355

APA Style

Hou, Z., Lin, S., Du, T., Wang, M., Wang, W., You, S., Xue, N., Liu, Y., Ji, M., Xu, H., & Chen, X. (2025). Correction: Hou et al. S-72, a Novel Orally Available Tubulin Inhibitor, Overcomes Paclitaxel Resistance via Inactivation of the STING Pathway in Breast Cancer. Pharmaceuticals 2023, 16, 749. Pharmaceuticals, 18(9), 1355. https://doi.org/10.3390/ph18091355

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop